Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nitazoxanide

FDA-approved product (tablet, oral), marketed as Alinia, Nitazoxanide.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Nitazoxanide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Amebiasis
  • Diarrhea

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other agents against amoebiasis and other protozoal diseases
FDA pharmacologic class
Antiprotozoal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01AX11; FDA class Antiprotozoal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA36.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis77.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 1 of 1 lab record
Open Nitazoxanide in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nitazoxanide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19

    NCT04498936 · start 2020-07-15

    Registered record
    Registry ID
    NCT04498936
    Conditions
    COVID
    Interventions
    Sofosbuvir and Ledipasvir; Nitazoxanide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-07-15
    Completion
    2020-10-30
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID
    InterventionSofosbuvir and Ledipasvir; Nitazoxanide
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients

    NCT04441398 · start 2020-07

    Registered record
    Registry ID
    NCT04441398
    Conditions
    covid19
    Interventions
    Nitazoxanide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Withdrawn
    Start
    2020-07
    Completion
    2020-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    Conditioncovid19
    InterventionNitazoxanide; Placebo
    PhasePhase 2 / Phase 3
    Registry statusWithdrawn

  • EAT-DUTA AndroCoV Trial

    NCT04729491 · start 2020-06-30

    Registered record
    Registry ID
    NCT04729491
    Conditions
    Covid19
    Interventions
    Dutasteride 0.5 mg; Azithromycin; Nitazoxanide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2020-06-30
    Completion
    2020-10-07
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19
    InterventionDutasteride 0.5 mg; Azithromycin; Nitazoxanide; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19)

    NCT04463264 · start 2020-06-26

    Registered record
    Registry ID
    NCT04463264
    Conditions
    COVID-19
    Interventions
    Nitazoxanide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2020-06-26
    Completion
    2020-12-26
    Enrolment
    135

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionNitazoxanide; Placebo
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19

    NCT04348409 · start 2020-05-25

    Registered record
    Registry ID
    NCT04348409
    Conditions
    COVID-19
    Interventions
    Nitazoxanide Tablets; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-05-25
    Completion
    2020-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionNitazoxanide Tablets; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide

    NCT04406246 · start 2020-05-21

    Registered record
    Registry ID
    NCT04406246
    Conditions
    Coronavirus Infection
    Interventions
    Nitazoxanide 500Mg Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-05-21
    Completion
    2020-12-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection
    InterventionNitazoxanide 500Mg Oral Tablet
    PhasePhase 4
    Registry statusCompleted

  • Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19

    NCT04361318 · start 2020-05

    Registered record
    Registry ID
    NCT04361318
    Conditions
    COVID-19
    Interventions
    Hydroxychloroquine plus Nitazoxanide; Standard care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2020-05
    Completion
    2020-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionHydroxychloroquine plus Nitazoxanide; Standard care
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Treatment of Cryptosporidiosis

    NCT04103216 · start 2020-02-01

    Registered record
    Registry ID
    NCT04103216
    Conditions
    Cryptosporidiosis
    Interventions
    Nitazoxanide with Lactobacillus Reuteri DSM 17938; Nitazoxanide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-02-01
    Completion
    2023-08-31
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCryptosporidiosis
    InterventionNitazoxanide with Lactobacillus Reuteri DSM 17938; Nitazoxanide
    PhaseNot applicable
    Registry statusCompleted

  • Nitazoxanide as a New Local Adjunctive to Nonsurgical Treatment of Moderate Periodontitis

    NCT04768530 · start 2019-07-20

    Registered record
    Registry ID
    NCT04768530
    Conditions
    Periodontitis
    Interventions
    Scaling and Root Planing; Nitazoxanide hydrogel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-07-20
    Completion
    2020-04-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeriodontitis
    InterventionScaling and Root Planing; Nitazoxanide hydrogel
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

    NCT03605862 · start 2018-09-11

    Registered record
    Registry ID
    NCT03605862
    Conditions
    Enterovirus; Rhinovirus
    Interventions
    Nitazoxanide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-09-11
    Completion
    2019-02-04
    Enrolment
    1,756

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnterovirus; Rhinovirus
    InterventionNitazoxanide; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Unique Regimen for Treatment of Helicobacter Pylori Infection

    NCT03491995 · start 2018-04-01

    Registered record
    Registry ID
    NCT03491995
    Conditions
    Helicobacter Infections
    Interventions
    Quadruple therapy; Classic treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2018-04-01
    Completion
    2023-04-01
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Infections
    InterventionQuadruple therapy; Classic treatment
    PhasePhase 3
    Registry statusUnknown

  • Early Life Interventions for Childhood Growth and Development In Tanzania

    NCT03268902 · start 2017-09-05

    Registered record
    Registry ID
    NCT03268902
    Conditions
    Malnutrition; Stunting; Cognitive Development; Enteric Pathogens
    Interventions
    Azithromycin Oral Liquid Product; Nitazoxanide Oral Suspension; Nicotinamide; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2017-09-05
    Completion
    2020-03-26
    Enrolment
    1,188

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalnutrition; Stunting; Cognitive Development; Enteric Pathogens
    InterventionAzithromycin Oral Liquid Product; Nitazoxanide Oral Suspension; Nicotinamide; Placebos
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis

    NCT02684240 · start 2016-02

    Registered record
    Registry ID
    NCT02684240
    Conditions
    Tuberculosis
    Interventions
    Nitazoxanide; Control
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-02
    Completion
    2018-04-11
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionNitazoxanide; Control
    PhasePhase 2
    Registry statusCompleted

  • Nitazoxanide Plus Lactulose Versus Lactulose Alone Treatment of Hepatic Encephalopathy

    NCT02464124 · start 2016-01

    Registered record
    Registry ID
    NCT02464124
    Conditions
    Encephalopathy, Hepatic
    Interventions
    Nitazoxanide; Lactulose
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2016-01
    Completion
    2017-12
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEncephalopathy, Hepatic
    InterventionNitazoxanide; Lactulose
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

    NCT02612922 · start 2015-12

    Registered record
    Registry ID
    NCT02612922
    Conditions
    Influenza
    Interventions
    Nitazoxanide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-12
    Completion
    2016-09-04
    Enrolment
    325

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfluenza
    InterventionNitazoxanide; Placebo
    PhasePhase 3
    Registry statusCompleted